Vir Biotechnology, Inc. — Director's Dealing 2021

Dec 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-11-30

Reporting Person: Rice Steven J. (Chief Administrative Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-30	Common Stock	M	10000	$12.76	Acquired	30600	Direct
2021-11-30	Common Stock	S	10000	$50.00	Disposed	20600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-30	Employee Stock Option (Right to Buy)	$12.76	M	10000	Disposed	2029-12-10	Common Stock (10000)	Direct

Footnotes

F1: Includes 600 shares of common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F3: 1/4 of the shares subject to the stock option vest and become exercisable on September 15, 2020, and the remainder vest in 36 equal monthly installments thereafter.